Kornimate/medical-research-clean huggingface dataset:
multi-center trial of spect myocardial blood flow quantitation for detection of coronary artery disease

Conditions: Coronary Artery Disease

Summary: patients with suspected or known coronary artery disease who are scheduled for clinically indicated spect myocardial perfusion imaging (mpi) and will receive invasive coronary angiogram are recruited to receive spect mbf study.

patients with suspected or known coronary artery disease who are scheduled for clinically indicated spect myocardial perfusion imaging (mpi) and likely will further receive invasive coronary angiogram will be recruited for a spect mbf study. the mbf study will be performed as an adjunct to mpi utilizing the same rest and stress injections of 99mtc-sestamibi (mibi) tracer, and the same infusion of dipyridamole, adenosine or adenosine triphosphate for stressing. the mbf study will be completed in single or two days depending on the imaging protocol of mpi for a site. this is an observational study with no interventions to the clinical routine whatsoever. three models of spect (ge nm530c) and spect/ct (siemens symbia-t16 and -t2) cameras are included to acquire rest/stress dynamic spect and mpi data. a ct scan will be acquired for the purpose of attenuation correction. all dynamic images will be reconstructed with physical corrections, including attenuation, scatter, resolution recovery and noise reduction, and processed to quantify mbf with the same kinetic modeling. the imaging processing of mbf study will be conducted with a spect mbf dedicated software (myoflowq) in a central lab. mpi images will be collected and independently read by three consensus readers. the angiographic result will be independently reviewed by an interventional cardiologist. diagnostic performance of spect mbf and perfusion will be compared utilizing angiographic result as the reference standard.

Eligibility criteria:
inclusion criteria: * age 18 \~ 79 years old * any cad risk factor * cad related symptoms * intermediate to high probability of cad * suspected or known cad on a stable medication regime * able and willing to comply with the study procedures * written informed consent exclusion criteria: * history or risk of severe bradycardia * history of myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy, valve issue or congenital heart disease * wheezing asthma or copd * known second- or third-degree av block * known hypersensitivity to dipyridamole or adenosine * breastfeeding or pregnancy * claustrophobia or inability to lie still in a supine position * unwillingness or inability to provide informed consent
effect of vibratory tendon stimulation on muscle fatigue in the acute post-stroke phase

Conditions: Stroke; Stroke, Acute; Fatigue

Summary: it seems that prolonged vibratory stimulation of the anterior forearm in healthy subjects leads to fatigue of the muscles concerned, with a reduction in their strength. the aim of this study is to evaluate the impact of vibratory tendon stimulation on grip force fatigue during the acute post-stroke phase. the investigations will be carried out by a specialized physiotherapist from the neurology department. the experiment consists of three successive phases: * first : measurement of the maximum handgrip force before any vibratory stimulation and then after the three sessions of ten-minute vibration. * second : rest period * third: control phase with measurement of the maximum grip force every ten minutes without vibration.


Eligibility criteria:
inclusion criteria: * age:18 to 85 * acute stroke (less than 7 days) * paretic upper limb: 3 or 4 to the mrc score and able to obtain a value of at least 10 kilograms on the handgrip strength * able to sign a consent form * affiliated to a social insurance exclusion criteria: * person under tutorship or curatorship, * sleepiness * pregnancy or breastfeeding woman

Keywords: stroke vibration handgrip strength fatigue
prevalence of sars-cov-2 genome in tears of asymptomatic and moderately symptomatic covid-19 patients

Conditions: SARS-CoV-2

Summary: to evaluate the prevalence of sars-cov-2 genome in patients with asymptomatic and moderately symptomatic covid19.

patients attending to the covid19 screening facility of paris south university hospital and willing to participate to the study will have both nasopharyngeal and conjunctival swab for sars-cv-2 genome detection using pcr. the project will evaluate the prevalence of positive conjunctival swabs in patients with positive nasopharyngeal swab. these results will be corelated to symptoms of disease assessed with a standardized questionnaire.

Eligibility criteria:
inclusion criteria: * patients receiving diagnostic nasopharyngeal pcr for covid-19 as part of the usual care * age ≥ 18. * information and signature of consent * affiliated with a social security scheme or entitled exclusion criteria: * refusal to participate in the study * eye surgery less than 3 months old * unable to give informed consent * no coverage through the health insurance system * patient under judicial protection * patient on ame

Keywords: sars-cov-2 covid19 conjunctiva tears
study of generalized anxiety disorder

Conditions: Anxiety Disorder; Anxiety Disorders

Summary: this study is designed to evaluate the efficacy and safety in generalized anxiety disorder patients

this study was a multi-center, randomized, placebo-controlled, double-blinded (placebo run-in will be single-blinded), group comparison study. paroxetine 20mg/day (achieved via the starting dose of 10 mg/day for the first week) once daily, or placebo was orally administered once daily for 8 weeks (fixed dose was adopted in the treatment phase) in patients with gad. for subjects who were classed as non-responders at week 8, paroxetine at 30 to 40mg/day (once daily) or placebo (once daily) was orally administered with flexible titration regimen for 4 weeks (fixed dose was adopted in the treatment phase). the subjects underwent a taper phase in case they received paroxetine 40mg/day, paroxetine 30mg/day or placebo at treatment completion or study withdrawal. a follow-up examination was conducted after 1 to 5 weeks from the last dose of the investigational product. the overall study duration requiring subject participation was 10 to 20 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of generalized anxiety disorder (gad) according to diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria. * must give a written informed consent. but if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent. exclusion criteria: * have the following conditions currently or diagnosed in the past 24 weeks: major depressive episode, panic disorder without agoraphobia, panic disorder with agoraphobia, social phobia/social anxiety disorder (sad), agoraphobia without history of panic disorder, posttraumatic stress disorder, obsessive compulsive disorder, anorexia nervosa, bulimia nervosa, dysthymic disorder * current or history of schizophrenia, bipolar disorder or cyclothymic disorder. * psychotherapy or cognitive behavioral therapy other than supportive psychotherapy. * current or history of substance abuse (alcohol or drugs) or substance in past 24 weeks. * taken st. john's wort in past 4 weeks. * had electroconvulsive therapy (ect) in past 12 weeks. * had psychotherapy or cognitive behavioral therapy other than supportive psychotherapy within 24 weeks. * women who are pregnant or lactating, who may be pregnant, or who plan for pregnancy by 30 days after the completion of final dose. * pose a suicidal threat or have attempted suicide in past 24 weeks. * history of convulsive disorder (epilepsy, etc.). * significant unstable medical illness. * current or history of glaucoma. * history or complication of cancer or malignant tumor. * history of hypersensitivity to paroxetine.

Keywords: generalized anxiety disorder
antiangiogenic peptide vaccine therapy with gemcitabine in treating patient with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to evaluate the safety, and tolerability of hla-a\*2402 restricted epitope peptide vegfr1 and vegfr2 emulsified with montanide isa 51 in combination with gemcitabine

vascular endothelial growth factor receptor 1 and 2 (vegfr1 andvegfr2) are essential targets to tumor angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific ctl response in vitro and in vivo. according to these findings, in this trial, we evaluate the safety, tolerability and immune response of these peptide emulsified with montanide isa 51 in combination with gemcitabine

Eligibility criteria:
inclusion criteria: disease characteristics 1. locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer 2. measurable disease by ct scan patients characteristics 1. ecog performance status 0-2 2. life expectancy \> 3 months 3. laboratory values as follows 2,000/mm3 \< wbc \< 15000/mm3 platelet count ≥ 750,000/mm³ total bilirubin ≤ 1.5 x aspartate transaminase \< 150 iu/l alanine transaminase \< 150 iu/l creatinine ≤ 3.0 mg/dl 4. hla-a\*2402 5. able and willing to give valid written informed consent exclusion criteria: 1. pregnancy (women of childbearing potential: refusal or inability to use effective means of contraception) 2. breast-feeder 3. active or uncontrolled infection 4. prior chemotherapy, radiation therapy, or immunotherapy within 4 weeks 5. serious or aggravated wound 6. active or uncontrolled other malignancy 7. steroids or immunosuppressing agent dependant status 8. interstitial pneumonia 9. ileus 10. decision of unsuitableness by principal investigator or physician-in-charge
a study of ly3875383 in healthy participants and participants with hypertriglyceridemia

Conditions: Hypertriglyceridemia

Summary: the main purpose of this study is to determine the tolerability and side effects related to ly3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (tg) levels.the study will also assess how fast ly3875383 gets into the blood stream and how long the body takes to get rid of it. each enrolled participant will receive a single dose of either ly3875383 or placebo.the study will be conducted in four parts (a, b, c and d) and may last up to approximately 28 to 56 weeks including screening.


Eligibility criteria:
inclusion criteria: all participants: * have a body mass index (bmi) between 18.5 and 40 kilograms per square meter (kg/m²), inclusive. * males who agree to follow contraceptive requirements, or women not of childbearing potential (wnocbp). healthy participants (part a): • participants must be overtly healthy, as determined by medical evaluation. for part b: • participants must be first-generation japanese, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive japanese descent and born in japan. hypertriglyceridemia participants (parts c and d): for part c: * have history of very high triglyceride (lipid) level 500 mg/dl ≤ tg \<2000 mg/dl, which needs to be further confirmed at screening. * participants must be on a lipid-modifying diet and can be on stable lipid-lowering drugs (llds) for at least 8 weeks before screening and plan to continue the same throughout the study duration. for part d: * have history of high triglyceride (lipid) level between 150 mg/dl and 500 mg/dl inclusive at pre-screening or based on medical history and confirmed at screening and low-density lipoprotein cholesterol (ldl-c) level of ≥40 mg/dl. * participants must be on a stable moderate or high-intensity dose of a statin for at least 8 weeks before screening and plan to continue the same medication and dose throughout the study duration. exclusion criteria: all participants: * participants must not be currently participating in or completed a clinical trial within the last 30 days * have donated blood of more than 500 ml within the previous 3 months * have one of the following viral infections: hepatitis b virus, hepatitis c virus or human immunodeficiency virus (hiv). * participants must not be heavy alcohol drinkers or cigarette smokers. for part c: have active pancreatitis within the last 6 months
burst spinal cord stimulation (burst-scs) study

Conditions: Pain, Chronic; Failed Back Surgery Syndrome

Summary: recently a new form of spinal cord stimulation therapy called burst spinal cord stimulation (burst-scs) is available to treat chronic pain. the goal of this study is to learn more about how burst-scs works to reduce chronic pain. the study will examine chronic pain patients who have been deemed candidates for burst-scs therapy, and who have already been selected to receive a temporary externalized trial of burst-scs from their own doctors as part of their standard clinical care for chronic pain management. during the study, participants will be asked to complete a variety of evaluations at certain time points. in addition, there will be a randomized, double blind, crossover phase, where the particular effects of burst-scs and sham scs will be evaluated. the device used to deliver burst-scs and sham scs is the st. jude medical invisible trial system.


Eligibility criteria:
inclusion criteria: * men or women with chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with any of the following: failed back surgery syndrome and intractable low back and leg pain, and for whom burst-scs has been recommended as a treatment option * candidates who can speak, read, and understand english exclusion criteria: * subjects who are pregnant- as determined by verbal report or chart review * subjects with current, habitual, or previous use within the last 12 months of artificial nails, nail enhancements, or nail extensions that cover any portion of either thumbnail. exceptions, including brief and/or occasional use, may be permissible at the discretion of the principal investigator * subjects who are unable or unwilling to cooperate with clinical testing * subjects having any impairment, activity or situation that, in the judgement of the study coordinator or pi, would prevent satisfactory completion of the study protocol

Keywords: burst-scs chronic pain spinal cord stimulation
rct of pulp capping over carious exposure in adults

Conditions: Carious Exposure; Human Permanent First and Second Molars; Mature Teeth; Proximal Caries; Healthy Pulp; Reversible Pulpitis

Summary: this multicentre study was a randomized, controlled, parallel, patient-blinded, two-arm superiority trial with a 1:1 allocation ratio that followed the consort guidelines.the aim of this study was to investigate whether mta is more effective than a conventional calcium hydroxide liner (dycal®) as a direct pulp capping material in mature molar teeth with a carious pulpal exposure.

calcium hydroxide (ch) is considered the standard material for pulp capping with good results in cases with pulpal exposure as a result of dental trauma both in animal and clinical studies. however, in carious exposures, follow-up studies of direct pulp capping performed with ch based materials have shown increasing failure rates and the outcome has been considered uncertain. direct capping of carious exposures still remains a controversial treatment for mature teeth. a new material, mineral trioxide aggregate (mta) was introduced for root end filling material almost two decades ago. it is also suggested for pulp capping. mta cement has showed good sealing ability and bio-compatibility in animal studies. results from studies in humans corroborate the results from animal studies. although the overall results of pulp capping in human studies using mta are very positive, well designed and controlled clinical studies, especially involving carious exposures on adult teeth are lacking.at the time the present study was launched, there were no rcts comparing mta and ch as dpc materials and the histological evaluations have primarily been based on healthy teeth, thus undermining the generalizability of the results to adult patients with carious exposures.

Eligibility criteria:
inclusion criteria: * age 18-55 years * 1st and 2nd permanent molars * proximal caries to inner 1/3 of dentin (bite-wing) * apex closed, no periapical changes (apical radiograph) * no periodontal pockets deeper than 4mm * medical history non-contributory (incl.pregnancy) * no medication (no antibiotics during last month) * no signs or symptoms more severe than reversible pulpitis * positive response to electrical pulp test(ept) or cold test * written consent inclusion requires compliance with all the criteria listed exclusion criteria: * during the treatment there will be no pulpal exposure * the bleeding of the exposed pulp cannot be controled in 10 minutes

Keywords: carious exposure pulp capping mta dycal
visceral manipulation treatment to patients with non-specific neck pain with functional dyspepsia

Conditions: Neck Pain; Functional Dyspepsia

Summary: background: non-specific neck pain (ns-np) is characterized by pain in structures located in the region between the superior nuchal line and the spinal process of the first thoracic vertebra, without association with any specific systemic disease provided by multifactorial and/or little known causes. objective: the objective of the present study will be to verify the clinical effects of mv through visceral nociceptive inhibition in ns-np patients with functional dyspepsia. methods: in this study sixty ns-np patients with functional dyspepsia (age: 18 and 50 years) will be randomized in into two groups: visceral manipulation group (vmg) (n =30) and control group (cg) (n =30). the vmg will be treated with visceral manipulation to the stomach and liver wile cg received placebo treatment. the immediate effects and 7 days after treatment will be evaluated through pain, cervical range, and electromyographic activity of the upper trapezius.


Eligibility criteria:
inclusion criteria: * history of neck pain for a minimal period of the three months; * neck with restricted movement (active or passive) in at least one direction; * neck disability index considering score range of 11-24 (score out of a 50) ; * numerical rating scale (nrs) for perceived pain intensity considering 3-7 points on an 11-point; * presence of symptoms related to functional dyspepsia, according to the rome iii diagnostic criteria: uncomfortable postprandial fullness, early satiety, epigastric pain and epigastric burning, accompanied by no evidence of structural disease capable of explaining the symptoms . exclusion criteria: * individuals with history of neurological disorders (i.e., irradiated pain) or neck surgery; systemic disease; connective tissue disorder and herniated disc; * current pregnancy; * medical diagnosis of fibromyalgia; * physical therapy treatment with, massage, or acupuncture in the previous two weeks; * use of analgesic, muscle relaxant, psychotropic agent, or anti-inflammatory agent in the previous three days; * chronic neck pain resulting from a traumatic incident; chronic musculoskeletal condition (e.g., muscular disorder, polyarthritis).

Keywords: neck pain visceral manipulation functional dyspepsia electromyography pain
the use of neuromuscular electrical stimulation to reverse muscle atrophy in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study will be a small randomized clinical trial to test the effectiveness of neuromuscular electrical stimulation (nmes) to improve physical function and reverse muscle atrophy in patients with rheumatoid arthritis (ra). the investigators will also determine the mechanism by which nmes affects muscle hypertrophy and physical function. the proposed study will be the first step in demonstrating that nmes training is an effective alternative to highly intense volitional exercises (ve) in individuals with ra. after baseline testing, 60 individuals with ra will be randomly assigned to a 16-week nmes program or highly intense ve program. both programs will be applied based on the best current clinical evidence. subjects will be re-assessed after intervention. groups will be compared for differences in performance-based and self-reported lower extremity function, muscle volume, muscle strength, proportion and area of type i and ii muscle fibers, fat content, and muscle oxidative capacity from pre- to post-intervention. changes in physical function, muscle volume, and muscle strength will be correlated with proportion and area of type i and ii muscle fibers, fat content, and markers of muscle oxidative capacity.


Eligibility criteria:
inclusion criteria: * english-speaking * age 21 or older * diagnosed with ra for at least 5 years according to the criteria of the american college of rheumatology * independent ambulator exclusion criteria: * history of cardiovascular disease or uncontrolled hypertension (above 140/90 mmhg); * history of a quadriceps tendon or patellar tendon rupture; * history of previous adverse reaction associated with electrical stimulation treatment; * surgery to the dominant lower extremities within the past 6 months. * history of a neurological disorder that may affect lower extremity function, such as cerebrovascular accident or neuropathy, parkinson's disease, multiple sclerosis, etc.; * history of muscle disease such as muscular dystrophy; * change in medication regimen (excluding nsaid change) during the month prior to treatment; * current use of cholesterol-lowering medication; * history of malignancy during the last 5 years, excluding skin cancers other than melanoma; * current or anticipated pregnancy; * less than 70º of passive knee flexion; * are not willing to undergo needle biopsy. * participated in progressive resistance training or nmes training in the prior year; * prior adverse effects with local anesthesia.